Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 10c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NYSE: LCTX) | Delayed: 1.03 +0.02 (1.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.01 | 52 Week High | $ | |||
| Open | $1.03 | 52 Week Low | $ | |||
| Day High | $1.07 | P/E | N/A | |||
| Day Low | $1.01 | EPS | $ | |||
| Volume | 961,019 | |||||
